Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + cisplatin + etoposide
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bevacizumab + cisplatin + etoposide is a combination chemotherapy regimen used primarily in the treatment of small-cell lung cancer (SCLC), particularly extensive disease SCLC. This regimen combines the anti-angiogenic monoclonal antibody bevacizumab with the cytotoxic agents cisplatin and etoposide. Bevacizumab works by inhibiting vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels that supply tumors. Cisplatin and etoposide are traditional chemotherapy agents that target rapidly dividing cells. The combination has been studied in clinical trials for its efficacy in improving overall survival and disease control rates in cancer patients.
- Other names
- PE and Bev regimenmPEBev regimen
02
Targets
Beyond the preview
Go deeper on bevacizumab + cisplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + cisplatin + etoposide.